GoldBamboo.com - Knowledge is strong medicine
  

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome - Article


  Not Signed In - Sign In / Register






Amphotericin B Lipid Complex Injection

Abelcet; AmBisome; Amphotec


Clinical Trial: Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome

This study has been completed.

Sponsored by: Pfizer
Information provided by: AIDS Clinical Trials Information Service

Purpose

To compare the safety and effectiveness of fluconazole and amphotericin B as maintenance treatment for preventing the relapse of cryptococcal meningitis in patients with AIDS.

Condition Treatment or Intervention
Meningitis, Cryptococcal
HIV Infections
 Drug: Fluconazole
 Drug: Amphotericin B

MedlinePlus related topics:  AIDS;   Fungal Infections;   Meningitis;   Neurologic Diseases

Study Type: Interventional
Study Design: Treatment

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

Concurrent Medication: Allowed:

  • Antivirals such as zidovudine.
  • Prophylaxis (including aerosolized pentamidine) for Pneumocystis carinii pneumonia (PCP).
  • Pfizer must be notified if the patient is receiving ganciclovir (DHPG) at entry.

Concurrent Treatment: Allowed:

  • Radiation therapy for mucocutaneous Kaposi's sarcoma.

Patients must be oriented to person, place, and time, and able to give written informed consent.

  • Patients must have had an acute episode of cryptococcal meningitis that was documented by recovery and identification of Cryptococcus neoformans from lumbar cerebrospinal fluid (CSF) culture within 6 months prior to entry.
  • Minimum total dose of 15 mg/kg of amphotericin B must have been given (either alone or in combination with flucytosine) during primary therapy.
  • Patients need not be receiving amphotericin B at the time of randomization but must begin study maintenance therapy within 6 weeks of completion of primary amphotericin B therapy. Patients may receive maintenance amphotericin B during the period between completion of primary therapy and study entry.

Prior Medication: Allowed:

  • Antivirals such as zidovudine (AZT).
  • Prophylaxis (including aerosolized pentamidine) for Pneumocystis carinii pneumonia (PCP).

Exclusion Criteria

Co-existing Condition: Patients with the following are excluded:

  • Clinical evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
  • History of allergy or intolerance of imidazoles, azoles, or amphotericin B.
  • Moderate or severe liver disease.

Concurrent Medication: Excluded:

  • Ketoconazole.
  • Fluconazole.
  • Itraconazole.
  • Miconazole.
  • Any systemic imidazole or azole for more than 7 days after initiation of primary therapy for cryptococcosis.
  • Intrathecal amphotericin B.
  • Coumarin-type anticoagulants.
  • Oral hypoglycemics.
  • Barbiturates.
  • Phenytoin.
  • Immunostimulants.
  • Investigational drugs or approved (licensed) drugs for investigational indications.

Concurrent Treatment: Excluded:

  • Lymphocyte replacement.

Patients with the following are excluded:

  • Clinical evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
  • History of allergy or intolerance of imidazoles, azoles, or amphotericin B.
  • Moderate or severe liver disease.
  • Inability to take oral medications reliably.

Prior Medication: Excluded:

  • Ketoconazole.
  • Fluconazole.
  • Itraconazole.
  • Miconazole.
  • Any systemic imidazole or azole for more than 7 days after initiation of primary therapy for cryptococcosis.
  • Intrathecal amphotericin B.
  • Coumarin-type anticoagulants.
  • Oral hypoglycemics.
  • Barbiturates.
  • Phenytoin.
  • Immunostimulants.
  • Investigational drugs or approved (licensed) drugs for investigational indications.
  • Any exceptions to these prohibitions of concomitant medications must be approved by Pfizer Central Research.

Prior Treatment: Excluded:

  • Lymphocyte replacement.

Location Information


Alabama
      Univ of Alabama at Birmingham, Birmingham,  Alabama,  35294,  United States

Arizona
      Tucson Veterans Administration Med Ctr, Tucson,  Arizona,  85724,  United States

California
      Davies Med Ctr, San Francisco,  California,  94114,  United States

      Dr Richard Meyer, Los Angeles,  California,  90048,  United States

      Dr Paul Rothman, Sherman Oaks,  California,  91403,  United States

Delaware
      Wilmington Hosp / Med Ctr of Delaware, Wilmington,  Delaware,  19899,  United States

District of Columbia
      George Washington Univ Med Ctr, Washington,  District of Columbia,  20037,  United States

Florida
      Univ of Florida College of Medicine, Gainesville,  Florida,  32610,  United States

      Univ of South Florida, Tampa,  Florida,  33612,  United States

Georgia
      DeKalb Gen Hosp, Decatur,  Georgia,  30033,  United States

      Med College of Georgia, Augusta,  Georgia,  30912,  United States

      Shallowford Hosp, Decatur,  Georgia,  30033,  United States

      Emory Univ School of Medicine, Atlanta,  Georgia,  30303,  United States

Illinois
      Northwestern Univ Med School, Chicago,  Illinois,  60611,  United States

Maine
      Dr Michael Bach, Portland,  Maine,  04102,  United States

Maryland
      Univ of Maryland / Inst of Human Virology, Baltimore,  Maryland,  212011192,  United States

Massachusetts
      New England Med Ctr, Boston,  Massachusetts,  02111,  United States

      Univ Hosp, Boston,  Massachusetts,  02118,  United States

Michigan
      Henry Ford Hosp, Detroit,  Michigan,  48202,  United States

      Harper Hosp, Detroit,  Michigan,  48201,  United States

      Ann Arbor Veterans Administration Med Ctr, Ann Arbor,  Michigan,  48105,  United States

New Jersey
      Saint Michael's Med Ctr, Newark,  New Jersey,  07102,  United States

New York
      Columbia Univ, New York,  New York,  10032,  United States

      Jewish Hosp Ctr Affiliation, Jamaica,  New York,  11432,  United States

      Chelsea Village Med Ctr, New York,  New York,  10014,  United States

      Cabrini Med Ctr, New York,  New York,  10003,  United States

      Harlem AIDS Treatment Group / Harlem Hosp Ctr, New York,  New York,  10037,  United States

      Albany Med College / AIDS Treatment Ctr, Albany,  New York,  12203,  United States

North Carolina
      Bowman Gray School of Medicine / North Carolina Baptist Hosp, Winston Salem,  North Carolina,  27103,  United States

Ohio
      Cincinnati Veterans Adm Med Ctr / Univ Hosp, Cincinnati,  Ohio,  452670405,  United States

Pennsylvania
      Buckley Braffman Stern Med Associates, Philadelphia,  Pennsylvania,  19107,  United States

Texas
      United States Air Force Med Ctr, Lackland Air Force Base,  Texas,  782365300,  United States

      Southwest Texas Methodist Hosp, San Antonio,  Texas,  78229,  United States

      Univ TX San Antonio Health Science Ctr, San Antonio,  Texas,  78284,  United States

      Univ TX Galveston Med Branch, Galveston,  Texas,  77550,  United States

Virginia
      Richmond AIDS Consortium, Richmond,  Virginia,  23219,  United States

Washington
      Dr Philip C Craven, Tacoma,  Washington,  98405,  United States

      CHG-118 Group Health / Cooperative of Puget Sound, Seattle,  Washington,  98112,  United States

Canada, Ontario
      Saint Michael's Hosp, Toronto,  Ontario,  Canada

More Information

Publications

Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, Graybill JR, Sugar AM, McAuliffe VJ, Follansbee SE, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med. 1992 Mar 19;326(12):793-8.

Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992 Jan 9;326(2):83-9.

Study ID Numbers:  012D; 056-157
Record last reviewed:  May 1990
Last Updated:  October 13, 2004
Record first received:  November 2, 1999
ClinicalTrials.gov Identifier:  NCT00002074
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005


Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $50 a year, a savings of 50% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Amphotericin B Lipid Complex Injection.

August 28, 2008



Page Updated: June 1, 2005
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Insurance Quotes | Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Google Co-op | Health Forums

Copyright © 2004-2008 - Gold Bamboo LLC
All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.